Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

Victor L J L Thijssen, Ruben Postel, Ricardo J M G E Brandwijk, Ruud P M Dings, Irina Nesmelova, Sietske Satijn, Nicole Verhofstad, Yusaku Nakabeppu, Linda G Baum, Jeroen Bakkers, Kevin H Mayo, Françoise Poirier, Arjan W Griffioen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We describe that galectin-1 (gal-1) is a receptor for the angiogenesis inhibitor anginex, and that the protein is crucial for tumor angiogenesis. gal-1 is overexpressed in endothelial cells of different human tumors. Expression knockdown in cultured endothelial cells inhibits cell proliferation and migration. The importance of gal-1 in angiogenesis is illustrated in the zebrafish model, where expression knockdown results in impaired vascular guidance and growth of dysfunctional vessels. The role of gal-1 in tumor angiogenesis is demonstrated in gal-1-null mice, in which tumor growth is markedly impaired because of insufficient tumor angiogenesis. Furthermore, tumor growth in gal-1-null mice no longer responds to antiangiogenesis treatment by anginex. Thus, gal-1 regulates tumor angiogenesis and is a target for angiostatic cancer therapy.

Original languageEnglish
Pages (from-to)15975-80
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number43
DOIs
Publication statusPublished - 24 Oct 2006
Externally publishedYes

Cite this